sb.scorecardresearch

Published 16:24 IST, July 10th 2024

Zydus Lifesciences gets USFDA nod for heart failure treatment drug

Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.

Follow: Google News Icon
  • share
Top 10 Pharmaceutical Companies in India by Market Capitalisation
Top 10 Pharmaceutical Companies in India by Market Capitalisation | Image: Unsplash

Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to market its generic Sacubitril and Valsartan tablets combination used to treat chronic heart failure in adults.

The approval by the US Food and Drug Administration (USFDA) is to market Sacubitril and Valsartan tablets of strengths 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Zydus Lifesciences said in a regulatory filing.

Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.

The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company added. 

Updated 16:24 IST, July 10th 2024